title: [Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer].
abstract: OBJECTIVE
  A previous large randomized control study(IALT)revealed that cisplatin(CDDP)-based adjuvant chemotherapy was not effective for patients with ERCC1-positive non-small cell lung cancer(NSCLC). We evaluated the chemosensitivity of surgically resected specimens of NSCLC using in vitro chemosensitivity test and searched for promising adjuvant chemotherapy protocols in the ERCC1-positive subgroup of NSCLC.
  
  
  METHODS
  Chemosensitivities of 10 anticancer agents including cisplatin were evaluated by histoculture drug response assay(HDRA) using 28 surgically resected NSCLC specimens. ERCC 1 status was evaluated by immunohistochemistry.
  
  
  RESULTS
  ERCC1 was positive in 22 and negative in 6 specimens. All ERCC1-negative specimens were sensitive for CDDP in HDRA, and all CDDP-resistant specimens in HDRA showed positive ERCC1 staining. ERCC1 status was significantly correlated with CDDP sensitivity(p=0.01). HDRA showed average 3(0-6)sensitive anticancer agents except for CDDP even in ERCC1-positive specimens.
  
  
  CONCLUSIONS
  HDRA may provide effective non-platinum adjuvant chemotherapy protocols for patients with ERCC1-positive, i.e. CDDP resistant, NSCLC.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University.
authors.forename: Yoshimitsu
authors.initials: Y
authors.lastname: Hirai
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Yoshimasu
authors.forename: Shoji
authors.initials: S
authors.lastname: Oura
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tamaki
authors.forename: Fuminori
authors.initials: F
authors.lastname: Ota
authors.forename: Rie
authors.initials: R
authors.lastname: Nakamura
authors.forename: Yukio
authors.initials: Y
authors.lastname: Shimizu
authors.forename: Koma
authors.initials: K
authors.lastname: Naito
authors.forename: Megumi
authors.initials: M
authors.lastname: Ota
authors.forename: Miwako
authors.initials: M
authors.lastname: Miyasaka
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Okamura
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Hironao
authors.initials: H
authors.lastname: Yasuoka
authors.forename: Rieko
authors.initials: R
authors.lastname: Kodama
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001681:Biological Assay / Q000379:methods*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D004268:DNA-Binding Proteins / Q000032:analysis* / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004720:Endonucleases / Q000032:analysis* / Q000378:metabolism*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D046509:Tissue Culture Techniques
chemical_list: D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; C071447:ERCC1 protein, human; D004720:Endonucleases